The multiple myeloma market is evolving toward immunotherapy-dominated, multi-line treatment paradigms with strong growth driven by CAR-T and bispecific antibodies. Leading contenders advancing through the pipeline include AZD0120 [AstraZeneca (Gracell Biotechnologies)], VENCLEXTA (venetoclax, ABT199 and RG7601) [AbbVie and Roche (Genentech)], Anito-cel (CART-ddBCMA) [Arcellx/Gilead (Kite)], Etentamig (ABBV-383) (AbbVie/TeneoOne), Iberdomide (CC-220) [Bristol-Myers Squibb (Celgene)], BMS-986393